. 2021 Jul 13;326(2):137–144. doi: 10.1001/jama.2021.6986

Table 3. Secondary Outcomes by Treatment Group and Time^a.

	Platelet-rich plasma		Sham^b		Between-group difference (95% CI)
	No.	Mean (SD)	No.	Mean (SD)	Unadjusted	P value	Adjusted^c	P value
Pain VAS^c
2 wk	113	3.7 (2.5)	116	4.1 (2.7)	−0.3 (−1.0 to 0.3)	.33	−0.1 (−0.7 to 0.6)	.85
3 mo	116	3.6 (2.6)	111	3.6 (2.6)	0.0 (−0.7 to 0.7)	.95	0.2 (−0.4 to −0.9)	.47
6 mo	110	2.7 (2.6)	111	2.6 (2.7)	0.2 (−0.5 to 0.9)	.64	−0.4 (−0.3 to 1.1)	.22
EQ-5D-5L VAS^d
3 mo	116	67.6 (19.7)	111	69.0 (19.3)	−1.4 (−6.5 to 3.7)	.59	−2.6 (−7.9 to 2.7)	.33
6 mo	110	72.8 (18.7)	111	72.7 (19.7)	0.2 (−4.9 to 5.2)	.95	−0.6 (−5.8 to 4.7)	.81
EQ-5D-5L utility score^e
3 mo	116	0.654 (0.198)	111	0.639 (0.211)	0.014 (−0.039 to 0.068)	.59	−0.005 (−0.057 to 0.047)	.85
6 mo	110	0.690 (0.214)	111	0.674 (0.217)	0.016 (−0.041 to 0.073)	.58	−0.002 (−0.059 to 0.055)	.94

Abbreviations: EQ-5D-5L, 5-level Euroqol questionnaire; VAS, Visual Analog Scale; VISA-A, Victorian Institute of Sport Assessment-Achilles score.

^{^a}

Analysis was adjusted for age, sex, laterality, and baseline VISA-A score, with site included as a random effect. A lower pain VAS score indicates less pain. A higher EQ-5D-5L index/VAS score indicates better health-related quality of life.

^{^b}

Sham is subcutaneous injection of a dry needle.

^{^c}

Score range: 0 (no pain) to 10 (worst pain) with a score of 4 to 5 indicating moderate pain.

^{^d}

Score range: 0 (indicates worst health) to 100 (best health).

^{^e}

The score indicates a composite measure of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels (range, usually 0 to 1 [best health-related quality of life]), but negative values are possible and indicate worse than death.

Table 3. Secondary Outcomes by Treatment Group and Timea.

Table 3. Secondary Outcomes by Treatment Group and Time^a.